Premier Research Group announces the re-branding of its Medical Device business unit to D-TARGET, a Premier Research Company. With the continued growth in clinical development activity driven by rising regulatory and commercial demands in the medical device industry, Premier Research recognizes this sector has specific needs.
D-TARGET was founded in 1997 and acquired by Premier Research in 2007. By reintroducing the name, Premier Research reinforces its focus on this sector and highlights the capability, expertise, and experience gained by its staff operating as a dedicated Medical Device Contract Research Organization.
This division offers a team of medical device specialists with experience in the European Union and North America. D-TARGET’s staff is located in more than 30 countries with primary offices in Yverdon, Switzerland and Boston, Massachusetts. Sponsors directly benefit from regional employees with their knowledge of the local clinical research environment and ability to communicate with investigators and regulatory bodies in their own local language.
D-TARGET continues to offer a total life cycle partnership for developers of medical device and combination products, ranging from: strategic and tactical advisory services, clinical trial set-up, and clinical trial operations through to post marketing surveillance and registry support. In conjunction with the clinical operational staff, D-TARGET has specialist support groups dedicated to: regulatory affairs, ethical committee, competent authority, and country specific submissions, protocol writing, statistical analysis, and data management, thereby enabling our teams to meet the full range of needs of medical device developers worldwide.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.